Our Science

Our scientific endeavors at Calidi Biotherapeutics are driven by rigorous research, innovative approaches, and an unwavering commitment to combating solid tumors. We continuously explore the immense potential of immunotherapies, striving to redefine the boundaries of what's possible in cancer treatment.

A person in a lab coat and purple gloves working on a machine.
A person in blue gloves is holding a tube.
A man in a lab coat and goggles looking at a box.
How It WorksNovel PlatformPublications

How the Calidi platforms work

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

Our pipeline is robust and ever-evolving, driven by our commitment to pioneering breakthroughs in cancer treatment.

Explore Pipeline

Something about the benefits of tech

Our top features are designed to provide you with a seamless experience and make your treatments as easy as possible.

Scientific Publications

Publication
event
NeuroNova & Supernova
Neuronova
SuperNova
RTNOVA

Annual Meeting – SITC 2023 – Nov 1st to 5th 2023 in San Diego, CA, USA.

SUPERNOVA1 (SNV1), A NOVEL ONCOLYTIC-CELL BASED PLATFORM FOR CANCER THERAPY

November 3, 2023
Discover More
Read More
Publication
event
NeuroNova & Supernova
Neuronova
SuperNova
RTNOVA

Development of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic Virotherapy

National Center for Biotechnology Information

December 13, 2022
Discover More
Read More
Publication
event
NeuroNova & Supernova
Neuronova
SuperNova
RTNOVA

Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial

Lancet Oncology

August 22, 2021
Discover More
Read More
Publication
event
NeuroNova & Supernova
Neuronova
SuperNova
RTNOVA

Abstract 4473: Evaluation of the potential of oncolytic vaccinia virus delivered by autologous SVF to modulate innate and adaptive immunity in patients with diverse solid and hematological malignancies

American Association for Cancer Research

August 15, 2020
Discover More
Read More
Publication
event
NeuroNova & Supernova
Neuronova
SuperNova
RTNOVA

Abstract 6542: CAL1 vaccinia virus as oncolytic agent and potential use of cell-based platform to enhance its therapeutic effects

American Association for Cancer Research

August 15, 2020
Discover More
Read More
Publication
event
NeuroNova & Supernova
Neuronova
SuperNova
RTNOVA

Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms.

Journal of Clinical Oncology

May 25, 2020
Discover More
Read More
Publication
event
NeuroNova (NNV)
Neuronova
SuperNova

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

The Journal of Translational Medicine

August 19, 2019
Discover More
Read More
Publication
event
NeuroNova (NNV)
Neuronova
SuperNova

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Abstract P609: First in man study of TK positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

November 7, 2018
Discover More
Read More
Publication
event
NeuroNova (NNV)
Neuronova
SuperNova

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Abstract P617: A cell-based platform to protect and enhance oncolytic virus therapies

November 7, 2018
Discover More
Read More
Publication
event
NeuroNova (NNV)
Neuronova
SuperNova

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer | November 7-11, 2018 Washington, D.C.

November 7, 2018
Discover More
Read More
Publication
event
SuperNova (SNV)
Neuronova
SuperNova

Abstract 4473: Evaluation of the potential of oncolytic vaccinia virus delivered by autologous SVF to modulate innate and adaptive immunity in patients with diverse solid and hematological malignancies

American Association for Cancer Research

August 15, 2020
Discover More
Read More
Publication
event
SuperNova (SNV)
Neuronova
SuperNova

Abstract 6542: CAL1 vaccinia virus as oncolytic agent and potential use of cell-based platform to enhance its therapeutic effects

American Association for Cancer Research

August 15, 2020
Discover More
Read More
Publication
event
SuperNova (SNV)
Neuronova
SuperNova

Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms.

Journal of Clinical Oncology

May 25, 2020
Discover More
Read More
Publication
event
SuperNova (SNV)
Neuronova
SuperNova

A cell-based platform to potentiate oncolytic virus: Potential approach for cancer therapies.

Journal of Clinical Oncology

February 4, 2020
Discover More
Read More
Publication
event
SuperNova (SNV)
Neuronova
SuperNova

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

The Journal of Translational Medicine

August 19, 2019
Discover More
Read More
Publication
event
SuperNova (SNV)
Neuronova
SuperNova

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

The Journal of Translational Medicine

March 27, 2019
Discover More
Read More
Publication
event
RTNova
Neuronova
SuperNova
RTNova

Transforming all Tumor Sites: The Power of Systemic Enveloped Virotherapy

SITC 2024

November 13, 2024
Discover More
Read More
Press Release
event
RTNova
Neuronova
SuperNova
RTNova

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics, Inc. will present data on RTNova, its systemic antitumor virotherapy platform, at several upcoming scientific conferences, including the International Oncolytic Virotherapy Conference in Rotterdam and Immuno US 2024 in San Diego. RTNova offers a novel approach to treating previously untreatable metastatic cancers by targeting multiple tumor sites and altering the tumor immune microenvironment. Dr. Antonio F. Santidrian and Dr. Duong H. Nguyen will lead these presentations, which have been crucial in advancing this innovative therapy.

October 24, 2024
Discover More
Read More
Press Release
event
RTNova
Neuronova
SuperNova
RTNova

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that it entered into a collaboration agreement with SIGA Technologies (Nasdaq: SIGA) in the first quarter of 2024, to support the development of Calidi’s systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.

June 10, 2024
Discover More
Read More
Publication
event
RTNova
Neuronova
SuperNova
RTNova

Transforming Tumor Immune Microenvironments with a Novel Systemic Enveloped Oncolytic Virotherapy Targeting All Tumor Sites

ASCO Annual Meeting 2024

June 1, 2024
Discover More
Read More

Calidi’s Contribution To The Treatment Of COVID-19

In A Short Time, The Novel Coronavirus Disease (COVID-19) Has Destructively Impacted Both The People Of The World And The Global Economy On A Historic Scale. As Of April 27th 2020, The World Health Organization (WHO) Reports Over 3,002,303 Confirmed Cases Globally, With The Worldwide Death Toll Rising Above 208,131.